A Phase 1 Study of ERAS-0015 in People With Solid Tumors

Full Title

A Phase 1 First-in-human Open-label study Evaluating the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics and Preliminary Efficacy of ERAS-0015 Monotherapy and in Combination in Patients with Advanced Solid Tumors

Purpose

Researchers want to find the highest dose of ERAS-0015 that can be given safely in people with advanced solid tumors. The people in this study have cancer that has metastasized (spread) and has a mutation in the RAS gene.

ERAS-0015 blocks a cell pathway that promotes the growth and spread of cancer. By blocking a group of proteins called RAS proteins, ERAS-0015 may help slow or stop the growth of your cancer. It is taken orally (by mouth).

Contact

For more information or to see if you can join this study, please call 646-888-4226.